Paraganglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aim of this study was to assess the safety and efficacy of the radiolabelled somatostatin analogue (177LutetiumDOTA0-Tyr3)octreotate (177Lu-DOTATATE) for the treatment of PGLs and PCCs.
|
31067510 |
2019 |
Paraganglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Performance of <sup>68</sup>Ga-DOTA-Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis.
|
30030341 |
2019 |
Paraganglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Similarly to what was observed in the major ampulla, 3 histotypes were found: (i) ampullary-type somatostatin-producing tumors (ASTs, 10 cases), characterized by somatostatin expression in most tumor cells, focal-to-extensive tubulo-acinar structures, often with psammoma bodies, MUC1 reactivity, and no or rare membranous reactivity for somatostatin receptor type 2A; (ii) gangliocytic paragangliomas (3 cases), characterized by the coexistence of 3 tumor cell types: epithelioid, often reactive for pancreatic polypeptide, ganglion-like cells, and S100 reactive sustentacular/stromal cells; and (iii) ordinary nonfunctioning NETs (3 cases), resembling those more commonly observed in the extra-ampullary duodenum.
|
30913089 |
2019 |
Paraganglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because SSTR profiles vary in PHEOs and PGLs, individual analysis is required for each tumor.
|
30529752 |
2019 |
Paraganglioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Since the European Association of Nuclear Medicine 2012 guidelines, the excellent results obtained with gallium-68 (<sup>68</sup>Ga)-labelled somatostatin analogues (SSAs) in recent years have simplified the imaging approach for PPGL patients that can also be used for selecting patients for peptide receptor radionuclide therapy as a potential alternative or complement to the traditional theranostic approach with iodine-123 (<sup>123</sup>I)/iodine-131 (<sup>131</sup>I)-labelled meta-iodobenzylguanidine.
|
31254038 |
2019 |
Paraganglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>68</sup>Ga-somatostatin receptor analogs and <sup>18</sup>F-FDG PET/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a meta-analysis.
|
29566550 |
2018 |
Paraganglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Somatostatin receptor imaging (SRI) was performed for suspected PC (n = 46) or PGL (n = 27) of which 36 were during primary assessment and 37 during secondary assessment (follow-up after surgery).
|
29741215 |
2018 |
Paraganglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Somatostatin receptor-targeting endoradiotherapy offers potential for treating metastatic pheochromocytomas and paragangliomas, an approach likely to benefit from combination radiosensitization therapy.
|
30288966 |
2018 |
Paraganglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Somatostatin receptor scintigraphy (SRS) was the reference imaging technique for staging of sporadic PGLs.
|
27887852 |
2017 |
Paraganglioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Evaluation of somatostatin, CXCR4 chemokine and endothelin A receptor expression in a large set of paragangliomas.
|
29163802 |
2017 |
Paraganglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pheochromocytomas/paragangliomas overexpress somatostatin receptors, and recent studies have already shown excellent results in the localization of sympathetic succinate dehydrogenase complex, subunit B, mutation-related metastatic pheochromocytomas/paragangliomas using (68)Ga-DOTATATE PET/CT.
|
26564322 |
2016 |
Paraganglioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High somatostatin receptor expression on the cell membrane of succinate dehydrogenase mutation-related pheochromocytoma and paraganglioma provides a potential target for imaging and therapy.
|
26152741 |
2015 |
Paraganglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Usefulness of Somatostatin Receptor Scintigraphy (Tc-[HYNIC, Tyr3]-Octreotide) and 123I-Metaiodobenzylguanidine Scintigraphy in Patients with SDHx Gene-Related Pheochromocytomas and Paragangliomas Detected by Computed Tomography.
|
25791839 |
2015 |
Paraganglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our objective was to compare the performance of gadolinium-enhanced magnetic resonance angiography, contrast-enhanced computed tomography, and [(123)I]metaiodo-benzylguanidine and somatostatin receptor scintigraphies for detecting head and neck and thoracic-abdominal-pelvic paragangliomas in SDHx mutation carriers.
|
23162105 |
2013 |
Paraganglioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of somatostatin receptors, dopamine D₂ receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas.
|
21335363 |
2011 |
Paraganglioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Familial cervical paragangliomas with lymph node metastasis expressing somatostatin receptor type 2A.
|
19936639 |
2010 |
Paraganglioma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity.
|
18310290 |
2008 |